Progression to the phase 2b cohort follows recommendation of the Safety Review Committee (SRC) after it reviewed positive ...

The company announced that it will cease development of Mosnodenvir, a drug candidate designed to be the first anti-viral treatment for dengue. It is unclear if another developer will license the ...

Island Pharmaceuticals Ltd (ASX:ILA) has successfully enrolled its first subjects for a Phase 2b clinical trial to test the ...

The main treatment is supportive and symptomatic treatment by fluid-replacement therapy. Discovery of a new antiviral drug for dengue is the best hope for treatment.

Dual-listed regenerative medicine company Avita Medical has seen its share price slide ~19% today on a downgrade of its ...

The dengue outbreak in Bangladesh remains a significant public health challenge, with recent data revealing 67 ...

Some diseases that have spread over the last few decades are untreatable with medicines. Recovery banks heavily on immunity & ...

Surveillance and testing improvements in Tamil Nadu led to a rise in reported dengue cases, but fewer deaths in 2024.

Janssen, a company of Johnson & Johnson, has also recently thrown in the towel in the fight against dengue. The company announced that it will cease development of a drug candidate designed to be the ...